O ligodendrocytes play a critical role in neuroprotection by both remyelination-dependent and remyelination-independent mechanisms and confer protection in both inflammatory and degenerative diseases that involve the central nervous system, including multiple sclerosis, Alzheimer's disease and potentially Parkinson's disease. [1] [2] [3] [4] Although accumulating data have supported a major role for inflammation in the susceptibility of oligodendrocytes to cuprizone, the molecular pathways that regulate oligodendrocyte survival have not been well established. Here, we report that the targeted mutation of either Cd24 or Siglecg, which forms an axis that selectively regulates the innate inflammatory response to danger-associated molecular patterns (DAMPs), protects mice against cuprizone-induced oligodendrocyte loss. Moreover, the systemic administration of CD24Fc, which is known to stimulate Siglec G signaling and suppress the inflammatory response in vivo, protects oligodendrocytes against chronic exposure to cuprizone. Our data suggest that the host response to cellular injury actively participates in oligodendrocyte loss and provides a new approach to maintain oligodendrocytes under pathological conditions.
Chronic exposure to cuprizone is a classical model to induce oligodendrocyte loss in rodents. 5 Several groups have reported that inflammation plays a critical role in the loss of oligodendrocytes. However, the nature of the initiating signal for oligodendrocyte loss has not been clearly delineated. Janeway proposed that innate immunity is initiated primarily via the pattern recognition of microbial products called pathogenassociated molecular patterns (PAMPs). 6, 7 Subsequently, Matzinger proposed a danger signal, subsequently termed DAMPs by others, as the key to initiate the innate immune response. 8 We previously showed that the inflammation induced by PAMPs and DAMPs can be discriminated by the CD24-Siglec G interaction because the targeted mutation of either gene selectively enhances the host response to DAMPs without affecting that to PAMPs. 9, 10 Here, we explore the potential contribution of the innate immune response to DAMPs by evaluating the impact of targeted mutations of the Cd24 or Siglecg genes on oligodendrocyte survival after chronic cuprizone treatment.
We treated age-and sex-matched WT, Cd24 −/− and Siglecg −/− mice 9,10 with CPZ for 4 weeks and killed the mice at 4 weeks after treatment. To monitor the recovery of oligodendrocytes, the mice were first treated for 5 weeks, allowed to recover for 10 days with normal chow for 10 days and were then killed for analysis. The Bregman-1 region ( Figure 1a ) was sectioned and analyzed for the number of oligodendrocytes by immunofluorescence staining using an anti-Oligo-2 antibody that specifically binds to all cells in the oligodendrocyte lineage. Representative images are shown in Figure 1b , and the summary data are shown in Figure 1c . As shown in Figure 1b , all three strains of mice had a comparable number of oligodendrocytes prior to CPZ treatment. These data suggest that Cd24 and Siglec G are not involved in the development of oligodendrocytes in this region. However, targeted mutations of either the Cd24 or Siglecg gene resulted in a more severe depletion of oligodendrocytes at 4 weeks after CPZ treatment. Moreover, although the oligodendrocyte numbers were fully restored after 10 days of the recovery period in WT mice, only partial recoveries were observed in Cd24 −/− and Siglecg −/− brains (Figure 1c ). These data demonstrate that the CD24-Siglec G axis protects oligodendrocytes against CPZ toxicities.
To determine whether the Siglec G agonist CD24Fc 9, 10 (patent No. US20130231464) can be administered systemically to protect oligodendrocytes, we first evaluated whether CD24Fc can be delivered to the CNS through systemic administration. We intraperitoneally injected 10 mg of CD24Fc into 8-week-old mice. Serum and CSF were collected at days 1, 7, 14, 21 and 28, and the amounts of CD24Fc were measured by Sandwich ELISA. As shown in Figure 1d , CD24Fc could be found in the CSF throughout the observation period of 4 weeks, with levels that were largely parallel to those observed in the plasma. The CSF CD24Fc levels were approximately 0.2-0.3% of the plasma levels. The levels found at 4 weeks were higher than the IC50 of CD24Fc in assays for inhibiting the production of inflammatory cytokines by macrophages (patent No. US20130231464).
We analyzed the protective effect of CD24Fc at 2 and 4 weeks after CPZ treatment, based on the in situ analysis of the Oligo2 + oligodendrocytes. The oligodendrocyte numbers at the Bregma-1 positions of the corpus callosum ( Figure 1e) were analyzed because this region demonstrated more pathological damage during CPZ treatment; CD24Fc treatment significantly increased the number of oligodendrocytes at both 2 and 4 weeks after CPZ treatment (Figure 1f) . Additional animals were kept on the cuprizone-containing diet for 5 weeks and then were allowed to recover (removal of cuprizone from the diet) for an additional 10 days prior to killing. Controls were maintained on normal chow. The mice were perfused transcardially with phosphate-buffered saline (PBS) followed by cold 4% paraformaldehyde in PBS. The brains were removed, fixed overnight in 4% paraformaldehyde, and transferred to cryoprotection solution. Coronal frozen sections (30 μm, free floating) were cut on a Leica sliding microtome. Free-floating sections were rinsed in PBS and blocked with 5% normal donkey or goat serum for 1 h at room temperature. Because the loss of oligodendrocytes is usually associated with reduced remyelination, we also evaluated whether the targeted mutation of either the CD24 or Siglecg gene caused accelerated demyelination. Surprisingly, we did not observe more severe demyelination in either strain of mice (data not shown). Moreover, despite increased oligodendrocyte survival in CD24Fc-treated mice, we did not detect improved remyelination (data not shown). These data suggested that improved oligodendrocyte survival may not be sufficient to induce remyelination. Additional studies are needed to identify the conditions under which remyelination can be improved in the context of improved oligodendrocyte survival.
Taken together, our data demonstrate that the CD24-Siglec G axis protects oligodendrocytes against CPZ killing, thus implicating the host response to DAMPs as an unrecognized culprit for oligodendrocyte loss in the CPZ model. This new insight into the pathogenesis of oligodendrocyte loss suggests a new approach to promote oligodendrocyte survival in vivo. Consistent with this notion, we showed that the systemic administration of CD24Fc, which binds to DAMPs 9,10 and works as an agonist for Siglec G 9,10 (patent No. US20130231464), is sufficient to protect oligodendrocytes against killing by CPZ. Since the loss of oligodendrocytes has been implicated in multiple neurodegenerative diseases, 1-4 our data suggest that the host response in cellular injuries may be explored for the therapeutic development of these intractable neurological diseases. Finally, it should be noted that CD24 is also known as a costimulatory molecule for the activation of T cells, 11 including autoreactive T cells, 12 and intrahepatic CD4 T cells. 13 Correspondingly, CD24Fc was also shown to inhibit autoimmune diseases. 14 Because CD24Fc phenocopies the genetic defect of the Cd24 gene in autoimmune diseases, 12, 14 it likely works through a different mechanism as an antagonist.
